Biggest News Aggregation in the World
๐Ÿ“ฐ Comparative Effectiveness News

Page 2 - Comparative Effectiveness News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Comparative Effectiveness. Real-time updates on events, politics, business and more.

Advances in the management of type 2 diabetes in adults

Type 2 diabetes is a chronic and progressive cardiometabolic disorder that affects more than 10% of adults worldwide and is a major cause of morbidity, mortality, disability, and high costs. Over the past decade, the pattern of management of diabetes has shifted from a predominantly glucose centric approach, focused on lowering levels of haemoglobin A1c (HbA1c), to a directed complications centric approach, aimed at preventing short term and long term complications of diabetes, and a pathogenesi...
United States Diabetes Prevention Programme American Diabetes Association Standards Of Care Drug Administration Action For Health Australian Diabetes Society
Source: bmj.com

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-...
United States South Korea T Ai Pei Raymond Urbanski Pharmaessentia Tpex Aaron Gerds
Source: yahoo.com

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad

Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C...
South Korea United States T Ai Pei Raymond Urbanski Pharmaessentia Tpex Aaron Gerds

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

GLP-1 receptor agonists lower adverse cardiac event risk in veterans with type 2 diabetes

1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse cardiac events (MACE) in veterans with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). 2. The addition of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was not associated with a primary reduction in major adverse cardiac
Misuse Of Observational Research Veterans Health Administration Minute Medicine Inc Rating Level Comparative Effectiveness Diabetes Drugs

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science